Why unexplained nerve damage is being studied for early Parkinson’s

Parkinson’s disease is usually discussed as a disorder identified through changes in movement, thinking or other nervous-system functions. The supplied current description of ClinicalTrials.gov study NCT06745011 identifies a different starting point for investigation: people who already have unexplained damage affecting multiple peripheral nerves. The researchers are testing whether findings in those nerves, the nerve supply to the heart and sleep could form an early pattern associated with Parkinson’s or related diseases.

The wording matters. The study describes a proposed model in which disease-related changes might still be confined to the peripheral nervous system at an early stage. It does not establish that this is what is happening in its participants. This is an observational human study designed to compare measurements and follow people over time.

The study begins with unexplained peripheral nerve damage

Idiopathic polyneuropathy means that multiple peripheral nerves are affected without an identified cause. The current registry description focuses on a selected group of adults with this condition who also have orthostatic hypotension or an abnormal 24-hour blood-pressure pattern and who have undergone cardiac MIBG scintigraphy. The study is therefore not testing a screening program in the general population. It is asking a narrower question among people who already have particular neurological or autonomic findings.

Cardiac MIBG scintigraphy is used to assess sympathetic nerve supply to the heart. The study divides participants according to whether that imaging indicates normal or abnormal cardiac sympathetic innervation. The scan is a grouping measurement, not a diagnosis of Parkinson’s disease. Its purpose in this design is to identify whether another feature, such as a sleep abnormality, appears more often in one group than the other.

The record describes an estimated enrollment of 100 people, with roughly 30 expected to fall into the abnormal-imaging group and 70 into the normal-imaging group. The planning calculation assumes that isolated REM sleep behavior disorder might be found in 35% of the abnormal group and 5% of the normal group. Those figures explain how the investigators planned the study; they are not observed results.

Sleep findings provide a baseline comparison

REM sleep behavior disorder, or RBD, refers to a clinical sleep disorder in which the normal stillness of REM sleep is disrupted by movements or vocal behavior. REM sleep without atonia, or RSWA, is a related but distinct measurement: the muscle relaxation normally associated with REM sleep is reduced or absent during testing. A person may therefore have RSWA as a sleep-study finding without the full clinical picture of RBD.

The primary baseline question is whether isolated RBD or RSWA is more prevalent among participants with idiopathic polyneuropathy and abnormal cardiac sympathetic innervation than among those with normal innervation. The study uses questionnaires and one-night video polysomnography, allowing investigators to compare reported symptoms with a measured sleep pattern.

This first comparison concerns what is already present when people enter the study. Finding both an abnormal heart-nerve scan and a sleep abnormality at that point could identify a group worth following, but it would not show which feature came first. It would also not reveal whether either finding predicts a later neurodegenerative diagnosis.

Five years can separate co-occurrence from development

The longitudinal part of the design addresses a different question. Participants are intended to be assessed again over five years for RSWA, isolated RBD, Parkinson’s disease, dementia with Lewy bodies or multiple system atrophy. The registry also describes clinical, cognitive, motor, autonomic and imaging assessments.

A baseline assessment can show prevalence: how many people in each group have a finding at enrollment. Follow-up can show development: whether participants who did not have that finding later acquire it, or whether a specified diagnosis emerges during observation. That sequence is why the planned follow-up matters. Co-occurrence at one time point cannot supply the same information as documented change across time.

The study’s proposed pattern would be stronger if abnormal cardiac sympathetic innervation were associated with sleep abnormalities at baseline and with more subsequent diagnoses or sleep changes during follow-up. Even then, an observational association would describe a risk pattern rather than prove an anatomical origin or direction of disease spread. It would not independently establish that the brain was unaffected when participants entered the study.

The current registry record lists an actual study start date of 13 May 2024, an estimated completion date of 1 May 2031 and an enrolling-by-invitation status. It also states that registry results are not posted. These are descriptions of the supplied current record and should not be projected backward as the recruitment state of the December 2024 entry.

What earlier risk recognition could make possible

For people with otherwise unexplained peripheral nerve disease, a combination of cardiac nerve findings, sleep measurements and later clinical changes could eventually help identify who may warrant closer neurological follow-up before a clear neurodegenerative diagnosis. That possibility depends on the pattern proving predictive, reproducible and useful beyond this particular cohort. The study does not by itself promise prevention, treatment or a reliable early-diagnosis tool.

The accompanying biobank could expand what researchers learn from the follow-up. Skin, blood, cerebrospinal fluid and faecal samples are collected so that biological measurements can be compared with later disease trajectories. If those samples reveal markers that add useful information to the clinical, sleep or imaging findings, they could support prognostic research for Parkinson’s disease and related alpha-synuclein disorders. That capability also remains conditional on the study finding relationships that hold up in future testing.

Key Sources

• Primary source: Prodromal Model of Parkinson's Disease Confined to The Peripheral Nervous System
  Government or Regulator · Clinical Trial · 2024-12-20